Source 1primary paper2025MED
Toolkit/bispecific antibodies
bispecific antibodies
Also known as: bsAbs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Engineered cellular therapies include chimeric antigen receptor T (CAR-T) cells or bispecific antibodies (bsAbs) for subsequent immune clearance
Usefulness & Problems
Why this is useful
Bispecific antibodies are described as part of engineered therapeutic strategies for subsequent immune clearance in HIV-1 cure efforts.; immune clearance in HIV-1 cure strategies
Source:
Bispecific antibodies are described as part of engineered therapeutic strategies for subsequent immune clearance in HIV-1 cure efforts.
Source:
immune clearance in HIV-1 cure strategies
Problem solved
They address the need for immune-mediated clearance within multimodal cure strategies.; supporting subsequent immune clearance
Source:
They address the need for immune-mediated clearance within multimodal cure strategies.
Source:
supporting subsequent immune clearance
Problem links
supporting subsequent immune clearance
LiteratureThey address the need for immune-mediated clearance within multimodal cure strategies.
Source:
They address the need for immune-mediated clearance within multimodal cure strategies.
Published Workflows
Objective: Provide a personalized, risk-adapted treatment framework for multiple myeloma by sequencing frontline combinations, maintenance strategies, and later-line cellular therapies according to patient and disease context.
Why it works: The review describes a management logic in which different therapy classes are integrated across frontline, maintenance, and relapsed/refractory settings to improve efficacy while adapting to patient frailty, cytogenetic risk, and prior treatment exposure.
CD38 targetingPI/IMiD combination therapyBCMA-targeted CAR-T therapyMRD-guided treatment adaptationphase 3 comparative clinical evaluationrisk-adapted treatment selectiontreatment sequencing
Stages
- 1.Frontline and relapsed regimen integration(functional_characterization)
This stage reflects the review's emphasis that phase 3 trials redefined management by integrating effective regimens across major treatment settings.
Selection: Use phase 3-supported novel agents, monoclonal antibodies, and PI/IMiD-based combinations in frontline and relapsed/refractory settings.
- 2.Maintenance to sustain remission(secondary_characterization)
The review states that lenalidomide-based maintenance remains central to sustaining remission.
Selection: Apply primarily lenalidomide-based maintenance strategies after earlier therapy phases.
- 3.Cellular therapy for heavily pretreated refractory disease(confirmatory_validation)
The review highlights BCMA-targeted CAR-T therapy as transforming outcomes in a later-line refractory population.
Selection: Use BCMA-targeted CAR-T therapies in heavily pretreated, triple-class refractory patients.
- 4.MRD-guided treatment adaptation and cessation evaluation(decision_gate)
The review identifies MRD-guided approaches and MRD validation for treatment cessation as future directions.
Selection: Evaluate MRD as a biomarker to guide treatment adaptation or cessation.
Objective: Develop an HIV-1 cure framework that combines neutralizing antibodies, precision genome editing, and latent reservoir management rather than relying on monotherapy.
Why it works: The abstract argues that combining complementary modalities can address limitations of ART and monotherapies by jointly targeting viral replication, latent reservoirs, and immune dysfunction.
induction of broadly neutralizing antibodiesprecision genome editinglatent virus reactivationimmune clearanceimmune system reconstitutionreversal of T-cell exhaustionEnv trimer vaccinationmRNA-lipid nanoparticle deliveryCRISPR/Cas genome editingshock and killCAR-T cell therapybispecific antibody therapystem cell transplantationimmune checkpoint inhibition
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
immune clearanceTechniques
No technique tags yet.
Target processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: actuator
Operational role: actuator. Implementation mode: genetically encoded. Cofactor status: cofactor requirement unknown.
Despite its potency in suppressing HIV-1 replication, antiretroviral therapy (ART) cannot eliminate latent viral reservoirs and is associated with several limitations, such as the need for lifelong treatment and the inherent risk of drug resistance.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
CAR-T cells and bispecific antibodies are engineered therapeutic modalities for subsequent immune clearance in HIV-1 cure strategies.
Engineered cellular therapies include chimeric antigen receptor T (CAR-T) cells or bispecific antibodies (bsAbs) for subsequent immune clearance
Current multimodal HIV-1 cure strategies face challenges including suboptimal Env vaccine immunogenicity, off-target effects and inefficient delivery of gene editing tools, incomplete latent virus reactivation, and limitations of preclinical models.
Despite these advances, challenges remain, including suboptimal immunogenicity of Env vaccines, off-target effects and inefficient delivery of gene editing tools, incomplete reactivation of latent viruses, and limitations of preclinical models.
Future work should optimize synergistic effects by improving Env trimer design, enhancing CRISPR targeting specificity, and developing preclinical models that better reflect human immunity.
Future research should focus on optimizing synergistic effects by improving Env trimer design, enhancing the targeting specificity of CRISPR systems, and developing preclinical models that more accurately reflect human immunity
ART suppresses HIV-1 replication but cannot eliminate latent viral reservoirs and has limitations including lifelong treatment need and risk of drug resistance.
Despite its potency in suppressing HIV-1 replication, antiretroviral therapy (ART) cannot eliminate latent viral reservoirs and is associated with several limitations, such as the need for lifelong treatment and the inherent risk of drug resistance.
Native-like Env trimer vaccines are used to induce broadly neutralizing antibodies in HIV-1 antibody-based interventions.
Antibody-based interventions primarily involve inducing broadly neutralizing antibodies (bNAbs) through native-like envelope (Env) trimer vaccines
Precision genome editing for HIV-1 cure can be achieved using CRISPR/Cas together with long-acting slow-effective release antiretroviral therapy.
Precision genome editing can be achieved by using clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) along with long-acting slow-effective release antiretroviral therapy.
Reservoir-targeted therapies are typically implemented by reactivating latent viruses using the shock and kill strategy.
Reservoir-targeted therapies are typically implemented by reactivating latent viruses using the "shock and kill" strategy.
mRNA-lipid nanoparticle delivery systems further enhance the efficacy of Env trimer vaccine-based antibody interventions.
with their efficacy further enhanced by mRNA-lipid nanoparticle delivery systems
The HIV-1 cure field has progressed from monotherapy to multimodal combination strategies including neutralizing antibodies, precision genome editing, and latent reservoir management.
The quest for an HIV-1 cure has progressed from monotherapeutic approaches to the combinations of multimodal strategies, including neutralizing antibodies, precision genome editing, and management of latent reservoirs.
Approval Evidence
1 source1 linked approval claimfirst-pass slug bispecific-antibodies
Engineered cellular therapies include chimeric antigen receptor T (CAR-T) cells or bispecific antibodies (bsAbs) for subsequent immune clearance
Source:
applicationsupports
CAR-T cells and bispecific antibodies are engineered therapeutic modalities for subsequent immune clearance in HIV-1 cure strategies.
Engineered cellular therapies include chimeric antigen receptor T (CAR-T) cells or bispecific antibodies (bsAbs) for subsequent immune clearance
Source:
Comparisons
Source-stated alternatives
The abstract contrasts bsAbs with CAR-T cells, vaccines, CRISPR/Cas genome editing, stem cell transplantation, and checkpoint inhibitors.
Source:
The abstract contrasts bsAbs with CAR-T cells, vaccines, CRISPR/Cas genome editing, stem cell transplantation, and checkpoint inhibitors.
Source-backed strengths
presented as an immune-clearance modality in combination cure strategies
Source:
presented as an immune-clearance modality in combination cure strategies
Compared with CAR-T
The abstract contrasts bsAbs with CAR-T cells, vaccines, CRISPR/Cas genome editing, stem cell transplantation, and checkpoint inhibitors.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an immune-clearance modality in combination cure strategies.
Source:
The abstract contrasts bsAbs with CAR-T cells, vaccines, CRISPR/Cas genome editing, stem cell transplantation, and checkpoint inhibitors.
Compared with CAR-T cells
The abstract contrasts bsAbs with CAR-T cells, vaccines, CRISPR/Cas genome editing, stem cell transplantation, and checkpoint inhibitors.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an immune-clearance modality in combination cure strategies.
Source:
The abstract contrasts bsAbs with CAR-T cells, vaccines, CRISPR/Cas genome editing, stem cell transplantation, and checkpoint inhibitors.
Compared with CAR-T cell therapy
The abstract contrasts bsAbs with CAR-T cells, vaccines, CRISPR/Cas genome editing, stem cell transplantation, and checkpoint inhibitors.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an immune-clearance modality in combination cure strategies.
Source:
The abstract contrasts bsAbs with CAR-T cells, vaccines, CRISPR/Cas genome editing, stem cell transplantation, and checkpoint inhibitors.
Compared with CAR-T therapy
The abstract contrasts bsAbs with CAR-T cells, vaccines, CRISPR/Cas genome editing, stem cell transplantation, and checkpoint inhibitors.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an immune-clearance modality in combination cure strategies.
Source:
The abstract contrasts bsAbs with CAR-T cells, vaccines, CRISPR/Cas genome editing, stem cell transplantation, and checkpoint inhibitors.
Compared with Chimeric Antigen Receptor (CAR) T-cell therapy
The abstract contrasts bsAbs with CAR-T cells, vaccines, CRISPR/Cas genome editing, stem cell transplantation, and checkpoint inhibitors.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an immune-clearance modality in combination cure strategies.
Source:
The abstract contrasts bsAbs with CAR-T cells, vaccines, CRISPR/Cas genome editing, stem cell transplantation, and checkpoint inhibitors.
Compared with chimeric antigen receptor T cells
The abstract contrasts bsAbs with CAR-T cells, vaccines, CRISPR/Cas genome editing, stem cell transplantation, and checkpoint inhibitors.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an immune-clearance modality in combination cure strategies.
Source:
The abstract contrasts bsAbs with CAR-T cells, vaccines, CRISPR/Cas genome editing, stem cell transplantation, and checkpoint inhibitors.
Compared with Chimeric antigen receptor T-cell therapy
The abstract contrasts bsAbs with CAR-T cells, vaccines, CRISPR/Cas genome editing, stem cell transplantation, and checkpoint inhibitors.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an immune-clearance modality in combination cure strategies.
Source:
The abstract contrasts bsAbs with CAR-T cells, vaccines, CRISPR/Cas genome editing, stem cell transplantation, and checkpoint inhibitors.
Compared with CRISPR/Cas9
The abstract contrasts bsAbs with CAR-T cells, vaccines, CRISPR/Cas genome editing, stem cell transplantation, and checkpoint inhibitors.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an immune-clearance modality in combination cure strategies.
Source:
The abstract contrasts bsAbs with CAR-T cells, vaccines, CRISPR/Cas genome editing, stem cell transplantation, and checkpoint inhibitors.
Compared with CRISPR/Cas9 system
The abstract contrasts bsAbs with CAR-T cells, vaccines, CRISPR/Cas genome editing, stem cell transplantation, and checkpoint inhibitors.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an immune-clearance modality in combination cure strategies.
Source:
The abstract contrasts bsAbs with CAR-T cells, vaccines, CRISPR/Cas genome editing, stem cell transplantation, and checkpoint inhibitors.
Compared with stem cell transplantation
The abstract contrasts bsAbs with CAR-T cells, vaccines, CRISPR/Cas genome editing, stem cell transplantation, and checkpoint inhibitors.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an immune-clearance modality in combination cure strategies.
Source:
The abstract contrasts bsAbs with CAR-T cells, vaccines, CRISPR/Cas genome editing, stem cell transplantation, and checkpoint inhibitors.
Ranked Citations
- 1.